Drug intelligence / Profile preview

NovaSOL astaxanthin

Development stage
Unknown
Lead developer
AquaNova
Modality
Small Molecules, Nanoparticles → Drug Delivery Systems
Administration
Oral
01

Overview

NovaSOL astaxanthin is a **micellar formulation of natural astaxanthin** developed by Aquanova that exhibits **superior antioxidant, anti-inflammatory, and neuroprotective properties** compared to standard astaxanthin formulations[1][3][5][7][10]. The micellar technology employed in NovaSOL increases the solubility and bioavailability of astaxanthin, resulting in more rapid and higher plasma concentrations following oral administration, which may enhance its therapeutic efficacy[7][10]. Astaxanthin itself is a carotenoid obtained from the microalgae *Haematococcus pluvialis*; this compound is not converted to vitamin A, does not show pro-oxidant activity, and must be supplied through diet[1][3][5]. NovaSOL astaxanthin is clinically studied for benefits including improved **skin health, muscle recovery, joint function, cardiovascular protection, neurological support, and immune modulation**, with demonstrated improvements in objective and subjective parameters of skin texture, hydration, and redness in human studies[9][12]. Its mechanisms of action involve **scavenging free radicals, enhancing endogenous antioxidant systems (ROS/RNS, SOD, GPX, Nrf2), modulating inflammatory pathways (NF-κB, MAPK, COX-2, IL-6, iNOS), regulating apoptosis (Bcl-2, p53, cyclin D1), improving metabolic and insulin signaling (PPARs, AMPK, IRS/PI3K/Akt), and protecting mitochondrial membranes**[2]. These distinct molecular and cellular impacts position NovaSOL astaxanthin as a nutraceutical for healthy aging, skin rejuvenation, muscle endurance/recovery, neurocognitive protection, and broad support of cardiovascular and immune function[1][3][5][9][12].

Brand names
NovaSOL ASTAXANTHIN
Other names
Astaxanthin micellar formulationMicellar astaxanthinNovaSOL astaxanthin
02

Targets

MAPK14 (p38 mitogen-activated protein kinase alpha)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)NOS2 (Nitric Oxide Synthase 2)AMPK (Adenosine monophosphate–activated protein kinase)BCL-2 (BCL-2 family)CCND1 (Cyclin D1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GPX4 (Glutathione peroxidase 4)IL-6 (Interleukin 6)MPTP (Mitochondrial permeability transition pore)MEKNF-κBPPAR (PPAR family)Misfolded SOD1TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on NovaSOL astaxanthin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaSOL astaxanthin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call